Abstract
Immune checkpoint-blocking drugs such as ipilimumab, pembrolizumab, and nivolumab have demonstrated clinical efficacy as anticancer agents. Through modulation of immunoregulatory molecules, these novel therapeutics can produce durable cancer remissions in a variety of tumor types. As these medications are administered to an increasing number of patients, clinicians must be able to recognize and treat the associated immune-related side effects. This review summarizes the unique mechanisms of toxicity associated with immune checkpoint-blocking drugs, appropriate steps in patient evaluation, and strategies for mitigating risk and optimizing patient outcomes. Although the management of each patient receiving immune checkpoint-blockade therapy must be individualized, a conceptual framework upon which to base a multidisciplinary approach to best practices will help oncology practitioners deliver safe and effective care.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 30-38 |
| Number of pages | 9 |
| Journal | Oncology |
| Volume | 28 |
| State | Published - Nov 1 2014 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Identification and management of toxicities from immune checkpoint-blocking drugs. / Teply, Benjamin A.; Lipson, Evan.
In: Oncology, Vol. 28, 01.11.2014, p. 30-38.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Identification and management of toxicities from immune checkpoint-blocking drugs
AU - Teply, Benjamin A.
AU - Lipson, Evan
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Immune checkpoint-blocking drugs such as ipilimumab, pembrolizumab, and nivolumab have demonstrated clinical efficacy as anticancer agents. Through modulation of immunoregulatory molecules, these novel therapeutics can produce durable cancer remissions in a variety of tumor types. As these medications are administered to an increasing number of patients, clinicians must be able to recognize and treat the associated immune-related side effects. This review summarizes the unique mechanisms of toxicity associated with immune checkpoint-blocking drugs, appropriate steps in patient evaluation, and strategies for mitigating risk and optimizing patient outcomes. Although the management of each patient receiving immune checkpoint-blockade therapy must be individualized, a conceptual framework upon which to base a multidisciplinary approach to best practices will help oncology practitioners deliver safe and effective care.
AB - Immune checkpoint-blocking drugs such as ipilimumab, pembrolizumab, and nivolumab have demonstrated clinical efficacy as anticancer agents. Through modulation of immunoregulatory molecules, these novel therapeutics can produce durable cancer remissions in a variety of tumor types. As these medications are administered to an increasing number of patients, clinicians must be able to recognize and treat the associated immune-related side effects. This review summarizes the unique mechanisms of toxicity associated with immune checkpoint-blocking drugs, appropriate steps in patient evaluation, and strategies for mitigating risk and optimizing patient outcomes. Although the management of each patient receiving immune checkpoint-blockade therapy must be individualized, a conceptual framework upon which to base a multidisciplinary approach to best practices will help oncology practitioners deliver safe and effective care.
UR - http://www.scopus.com/inward/record.url?scp=84925379870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925379870&partnerID=8YFLogxK
M3 - Article
C2 - 25384885
AN - SCOPUS:84925379870
VL - 28
SP - 30
EP - 38
JO - Oncology
JF - Oncology
SN - 0890-9091
ER -